TY - JOUR
T1 - Cannabidiol on the Path from the Lab to the Cancer Patient
T2 - Opportunities and Challenges
AU - Olivas-Aguirre, Miguel
AU - Torres-López, Liliana
AU - Villatoro-Gómez, Kathya
AU - Perez-Tapia, Sonia Mayra
AU - Pottosin, Igor
AU - Dobrovinskaya, Oxana
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/3
Y1 - 2022/3
N2 - Cannabidiol (CBD), a major non-psychotropic component of cannabis, is receiving grow-ing attention as a potential anticancer agent. CBD suppresses the development of cancer in both in vitro (cancer cell culture) and in vivo (xenografts in immunodeficient mice) models. For critical evaluation of the advances of CBD on its path from laboratory research to practical application, in this review, we wish to call the attention of scientists and clinicians to the following issues: (a) the biological effects of CBD in cancer and healthy cells; (b) the anticancer effects of CBD in animal models and clinical case reports; (c) CBD’s interaction with conventional anticancer drugs; (d) CBD’s potential in palliative care for cancer patients; (e) CBD’s tolerability and reported side effects; (f) CBD delivery for anticancer treatment.
AB - Cannabidiol (CBD), a major non-psychotropic component of cannabis, is receiving grow-ing attention as a potential anticancer agent. CBD suppresses the development of cancer in both in vitro (cancer cell culture) and in vivo (xenografts in immunodeficient mice) models. For critical evaluation of the advances of CBD on its path from laboratory research to practical application, in this review, we wish to call the attention of scientists and clinicians to the following issues: (a) the biological effects of CBD in cancer and healthy cells; (b) the anticancer effects of CBD in animal models and clinical case reports; (c) CBD’s interaction with conventional anticancer drugs; (d) CBD’s potential in palliative care for cancer patients; (e) CBD’s tolerability and reported side effects; (f) CBD delivery for anticancer treatment.
KW - adverse effects
KW - anticancer activity
KW - anticancer treatment
KW - cannabidiol
KW - clinical trials
KW - drug delivery
KW - palliative care
KW - pre-clinical studies
KW - synergism
UR - http://www.scopus.com/inward/record.url?scp=85127594823&partnerID=8YFLogxK
U2 - 10.3390/ph15030366
DO - 10.3390/ph15030366
M3 - Artículo de revisión
C2 - 35337163
AN - SCOPUS:85127594823
SN - 1424-8247
VL - 15
JO - Pharmaceuticals
JF - Pharmaceuticals
IS - 3
M1 - 366
ER -